Abbott FreeStyle Libre 4 Launches in China: AI Closed-Loop Insulin System Frees Diabetics from Finger Pricks

Overview

Abbott today officially launched the FreeStyle Libre 4 continuous glucose monitoring system in China, announcing simultaneously a partnership with Tsinghua University School of Medicine to open-source the AI insulin closed-loop system SugarBot — marking the beginning of true "autopilot" glucose management for Chinese diabetics.

How It Works

FreeStyle Libre 4 pairs with an insulin pump and AI algorithm to form a complete closed-loop control system:

1. Libre 4 automatically measures interstitial glucose every 5 minutes
2. The SugarBot AI calculates required insulin dosing based on glucose levels, meal plans, and activity data
3. The insulin pump automatically delivers basal rates and boluses
4. The entire process runs without any manual intervention

Patients colloquially call this the "glucose autopilot."

Clinical Data

Peking Union Medical College Hospital led Asia's largest closed-loop system clinical trial:

• Time in Range (TIR) improved from 62% to 83%
• Severe hypoglycemic events dropped by 76%
• Patient quality-of-life scores improved by 41%
• Average HbA1c reduction of 0.9%

China's Diabetic Population

China has the world's largest diabetic population, with over 140 million adults diagnosed. Diabetes-related complications generate annual medical expenditures exceeding ¥600 billion.

Pricing and Accessibility

Each Libre 4 sensor costs ¥420 and lasts 14 days — roughly ¥900 per month. Full insulin pump plus closed-loop system runs ¥30,000–80,000 upfront.

The system has been included in the medical insurance reimbursement catalogs of 8 provinces and cities including Beijing, Shanghai, and Zhejiang, reducing patient out-of-pocket costs to under 30%.

---